Related Experiment Video
Updated: Jun 11, 2026

Prion Safety Laboratory Swipe Test
Published on: February 14, 2025
Variant Creutzfeldt-Jakob disease
1National Creutzfeldt-Jakob Disease Surveillance Unit, Division of Pathology, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK. james.ironside@ed.ac.uk
Summary:
Variant Creutzfeldt-Jakob disease (CJD) is an emerging form of human prion disease caused by oral exposure to the bovine spongiform encephalopathy agent. Most cases have occurred in the UK, but smaller numbers of cases have been identified in 10 other countries worldwide. All confirmed cases belong to a single genetic subgroup defined by methionine homozygosity at codon 129 in the prion protein gene. Variant CJD has a widespread distribution of infectivity in the body, involving lymphoid tissues during at least the latter part of the incubation period. This is unlike other forms of human prion disease, and raised concerns that the transmissible agent might also be present in blood. To date, four probable cases of variant CJD infection have been identified following transfusion of packed red blood cells from asymptomatic donors who subsequently died from variant CJD. Recently, one case of likely transmission of variant CJD infection by UK factor VIII (FVIII) concentrates has been reported in an elderly haemophilic patient in the UK, who had been treated with FVIII produced from pooled plasma to which a donor who subsequently died from variant CJD had contributed. The recipient showed no signs or symptoms of variant CJD during life, but evidence of variant CJD infection was detected in his spleen following a postmortem examination. Continued surveillance is required to investigate the prevalence of secondary variant CJD infection in other patients with bleeding disorders who have been treated with UK-sourced pooled plasma products.
Insights
Variant Creutzfeldt-Jakob disease (vCJD), linked to bovine spongiform encephalopathy, shows widespread infectivity, including blood. Surveillance is crucial for secondary infections in patients receiving pooled plasma products.
Area of Science:
- Neuroscience
- Infectious Diseases
- Genetics
Background:
- Variant Creutzfeldt-Jakob disease (vCJD) is a human prion disease linked to bovine spongiform encephalopathy.
- Most vCJD cases are in the UK, with a specific genetic profile (methionine homozygosity at codon 129).
- vCJD exhibits widespread infectivity, including lymphoid tissues, raising concerns about bloodborne transmission.
Purpose of the Study:
- To investigate the potential for vCJD transmission through blood products.
- To assess the risk of secondary vCJD infections in patients treated with pooled plasma.
Main Methods:
- Surveillance of vCJD cases and their exposure history.
- Analysis of transfusion and treatment records for patients with bleeding disorders.
- Postmortem examination for evidence of vCJD infection.
Main Results:
- Four probable vCJD infections linked to packed red blood cell transfusions.
- One likely transmission of vCJD via UK factor VIII (FVIII) concentrates in a haemophilic patient.
- Evidence of vCJD infection found in the spleen of an asymptomatic recipient of FVIII concentrates.
Conclusions:
- vCJD can be transmitted through blood products, including packed red blood cells and pooled plasma derivatives like FVIII.
- Widespread infectivity in vCJD supports the risk of secondary transmission.
- Ongoing surveillance is essential to determine the prevalence of vCJD in patients treated with UK-sourced pooled plasma products.
Related Concept Videos
Cryptococcal Meningitis
Huntington Disease l: Introduction
Cytomegalovirus Disease
Alzheimer Disease ll: Pathophysiology
Arboviral Encephalitis
Encephalitis ll: Pathophysiology

